Completed PHASE3 INTERVENTIONAL 5-arm NCT01813604

Immunogenicity of Inactivated and Live Polio Vaccines

Phase III Clinical Trial to Assess the Immunogenicity of a Sequential Dose of Fractional Inactivated Polio Vaccine (f-IPV) and Oral Polio Vaccine (OPV)

Sponsor: Centers for Disease Control and Prevention

Conditions Poliomyelitis

Interventions Arm E: f-IPV and bOPV Group A: Trivalent Oral Polio Vaccine Group B: Bivalent Oral Polio Vaccine Group C: Inactivated Polio Vaccine Group D: fractional IPV (f-IPV)

Updated 6 times since 2017 Last updated: Jan 7, 2014 Started: Nov 30, 2012 Primary completion: Nov 30, 2013 Completion: Nov 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01813604, this PHASE3 trial focuses on Poliomyelitis and remains completed. Sponsored by Centers for Disease Control and Prevention, it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centers for Disease Control and Prevention
International Centre for Diarrhoeal Disease Research, Bangladesh
Ministry of Health and Family Welfare, Bangladesh
NanoPass Technologies Ltd

Data source: Centers for Disease Control and Prevention

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dhaka, Bangladesh